Bone Health in Adults With Severe Haemophilia Receiving Different Prophylactic Treatments
Haemophilia · 2026
DOI: 10.1111/hae.70215 ↗Kurz gefasst
Fachartikel in der Zeitschrift Haemophilia, 2026. Verfasst von Ting-Wei Lyu und 3 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hematology, Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan. Hauptthemen laut MEDLINE: Hemophilia A, Bone Density, Antibodies, Monoclonal, Humanized, Antibodies, Bispecific. Die Arbeit nennt 41 Literaturangaben. Gefördert von: National Taiwan University Hospital.
Abstract (Originalsprache)
Introduction
Haemophilia, an X‐linked disorder, is linked to reduced bone mineral density (BMD). Emicizumab, a factor VIII (FVIII) mimetic, provides a model to study the role of FVIII in bone health.
Aim
To evaluate BMD in adults with severe haemophilia under different prophylactic regimens, focusing on whether emicizumab maintains bone health comparable to FVIII prophylaxis.
Methods
Forty male adults with severe haemophilia A or B were prospectively enrolled at a single centre (2019–2024) and assigned to five prophylactic groups: emicizumab (with/without inhibitors), FVIII, factor IX (FIX) or investigational agents. Annual assessments included dual‐energy X‐ray absorptiometry, joint status, mobility and bone turnover markers.
Results
Of the 40 patients, 18 received FVIII, 10 FIX, 4 haemophilia A with inhibitors on emicizumab, 4 haemophilia A without inhibitors on emicizumab and 4 investigational therapies. At baseline, spine BMD z‐scores were comparable to age‐matched norms, whereas hip BMD was significantly lower (median –0.8; p < 0.001). After 1 year, spine and hip BMD changes did not differ significantly across treatment groups ( p = 0.9010 and p = 0.8073, respectively). Lower annual bleeding rate, middle age and BMI extremes were associated with BMD improvement. Emicizumab‐treated patients, with or without inhibitors, showed non‐inferior BMD outcomes compared to those receiving FVIII, with all 95% confidence intervals within the predefined margin (±0.5).
Conclusion
BMD outcomes did not differ across regimens. Emicizumab was comparable to FVIII, suggesting bleed control, not factor replacement, is key to bone health in haemophilia. Plain Language Summary People with haemophilia often have problems with joint bleeding, which can limit movement and reduce bone strength. Different treatments are now available to prevent bleeding, including factor replacement and newer medicines such as emicizumab. It is not clear whether these treatments affect bone health differently. In this study, we followed 40 adults with haemophilia and measured their bone health for 1 year. We found that bone outcomes were similar across all treatment groups. Emicizumab worked just as well as factor VIII in maintaining bone strength. This means that good bleeding control may be the key to keeping bones healthy in haemophilia, regardless of the treatment type.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Hematology, Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan.
- Division of Hematology, Department of Internal Medicine, National Taiwan University Hospital Hsin-Chu Branch, Hsinchu, Taiwan.
- Division of Metabolism, Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan.
- Graduate Institute of Clinical Medicine, College of Medicine, National Taiwan University, Taipei, Taiwan.
Förderung
- National Taiwan University Hospital
Zitieren
APA
Lyu, T. W., Chiu, W. Y., Sun, T., & Chou, S. C. (2026). Bone Health in Adults With Severe Haemophilia Receiving Different Prophylactic Treatments. Haemophilia. https://doi.org/10.1111/hae.70215
Vancouver
Lyu TW, Chiu WY, Sun T, Chou SC. Bone Health in Adults With Severe Haemophilia Receiving Different Prophylactic Treatments. Haemophilia. 2026. doi:10.1111/hae.70215
BibTeX
@article{Lyu2026,
author = {Lyu, Ting-Wei and Chiu, Wei-Yih and Sun, Ting and Chou, Sheng-Chieh},
title = {Bone Health in Adults With Severe Haemophilia Receiving Different Prophylactic Treatments},
journal = {Haemophilia},
year = {2026},
doi = {10.1111/hae.70215}
}
EUVIMED